Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.38 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641503 | 0.88 | CRBN (0.57) | DDB1CRBNHRH3 | |
| SCHEMBL30643634 | 0.88 | CRBN (0.57) | DDB1CRBNHRH3 | |
| SCHEMBL30830764 | 0.85 | DDB1 (0.51) | DDB1CRBNGPR119PARP1TNKS | |
| SCHEMBL30643638 | 0.84 | CRBN (0.58) | DDB1CRBNGPR119HRH3 | |
| SCHEMBL26641399 | 0.84 | CRBN (0.58) | DDB1CRBNGPR119HRH3 | |
| SCHEMBL30643707 | 0.80 | CRBN (0.59) | DDB1CRBNHRH3 | |
| SCHEMBL30830796 | 0.80 | DDB1 (0.53) | DDB1CRBNGPR119HRH3 | |
| SCHEMBL24319591 | 0.79 | DDB1 (0.58) | DDB1CRBNGPR119HRH3 | |
| SCHEMBL27162583 | 0.79 | DDB1 (0.58) | DDB1CRBNGPR119 | |
| SCHEMBL30643583 | 0.79 | CRBN (0.58) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |